Rituximab
Treatment for Rheumatoid Arthritis
Typical Dosage: 1000 mg IV on Day 1 and Day 15, repeated as needed (typically every 6-12 months)
Effectiveness
76%
Safety Score
38%
Clinical Trials
126
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
38
DangerousModerateSafe
Treatment Details
Dosage Range
1000 mg IV on Day 1 and Day 15, repeated as needed (typically every 6-12 months)
Time to Effect
8-12 weeks
Treatment Duration
Repeated every 6-12 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30,000
Monitoring:$3,000
Side Effect Mgmt:$1,500
Total Annual:$34,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$160,000/QALY
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$62,727.27
Cost per Remission
$172,500
Comparison vs Methotrexate
Cost Difference
+$32,900/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Rituximab Outcomes
for Rheumatoid Arthritis
Efficacy Outcomes
Overall Effectiveness
+76%
Response Rate
+55%
Remission Rate
+20%
Common Side Effects
Infusion reactions
+30%
Upper respiratory tract infections
+15%
Nausea
+8%
Serious infections
+4%
PML (Progressive Multifocal Leukoencephalopathy) (rare)
+0.1%
Active Clinical Trials
2 active trials recruiting for Rituximab in Rheumatoid Arthritis
Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis
NCT06175338ACTIVE NOT RECRUITINGPHASE1
208 participants
INTERVENTIONAL
Kaliningrad, Russia +11 more
Started: Jun 14, 2023
Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis
NCT06003283RECRUITINGPHASE4
134 participants
INTERVENTIONAL
Merksem, Belgium +6 more
Started: Jan 9, 2024
Completed Clinical Trials
13 completed trials for Rituximab in Rheumatoid Arthritis
PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis
NCT02819726COMPLETEDPHASE1
294 participants
INTERVENTIONAL
Anniston, United States +74 more
Started: Oct 11, 2016
Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis
NCT02296775COMPLETEDPHASE1, PHASE2
276 participants
INTERVENTIONAL
Hyderabad, India +27 more
Started: Nov 1, 2014
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor
NCT02079532COMPLETEDPHASE3
302 participants
INTERVENTIONAL
Bad Abbach, Germany +68 more
Started: Nov 1, 2006
A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)
NCT00422383COMPLETEDPHASE3
378 participants
INTERVENTIONAL
Coffs Harbour, Australia +90 more
Started: Feb 1, 2006
PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis
NCT02149121COMPLETEDPHASE3
384 participants
INTERVENTIONAL
Started: Aug 1, 2014
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
NCT01274182COMPLETEDPHASE1, PHASE2
312 participants
INTERVENTIONAL
Los Angeles, United States +56 more
Started: Jan 1, 2011
Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis
NCT01759030COMPLETEDPHASE3
181 participants
INTERVENTIONAL
Homyel, Belarus +39 more
Started: Dec 1, 2012
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent
NCT01641952COMPLETED
505 participants
OBSERVATIONAL
Bucharest, Romania
Started: Oct 1, 2011
Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)
NCT02304354COMPLETEDPHASE3
70 participants
INTERVENTIONAL
Brest, France +7 more
Started: Mar 9, 2015
A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies
NCT02097745COMPLETEDPHASE3
341 participants
INTERVENTIONAL
Mesa, United States +96 more
Started: Jun 1, 2004
MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis
NCT02468791COMPLETEDPHASE3
709 participants
INTERVENTIONAL
Banja Luka, Bosnia and Herzegovina +50 more
Started: May 1, 2013
An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis
NCT01613027COMPLETED
135 participants
OBSERVATIONAL
Athens, Greece +13 more
Started: Feb 1, 2012
An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)
NCT01075477COMPLETED
151 participants
OBSERVATIONAL
Hämeenlinna, Finland +7 more
Started: Sep 1, 2009
Showing 20 of 126 total trials